- Home
- SUZ vs AXSM Comparison
SUZ vs AXSM Comparison
Compare SUZ & AXSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SUZ | AXSM |
|---|---|---|
| Founded | 1924 | 2012 |
| Country | Brazil | United States |
| Employees | N/A | N/A |
| Industry | Paper | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.8B | 8.6B |
| IPO Year | 2002 | 2015 |
Fundamental Metrics
Financial Performance| Metric | SUZ | AXSM |
|---|---|---|
| Price | $8.88 | $217.74 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 17 |
| Target Price | N/A | ★ $211.12 |
| AVG Volume (30 Days) | ★ 2.5M | 811.4K |
| Earning Date | 05-11-2026 | 05-04-2026 |
| Dividend Yield | ★ 2.15% | N/A |
| EPS Growth | N/A | ★ 38.56 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $13.28 | $57.24 |
| Revenue Next Year | $13.57 | $55.88 |
| P/E Ratio | $5.58 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.52 | $96.09 |
| 52 Week High | $11.54 | $234.29 |
Technical Indicators
Market Signals| Indicator | SUZ | AXSM |
|---|---|---|
| Relative Strength Index (RSI) | 39.71 | 72.55 |
| Support Level | $8.80 | $148.87 |
| Resistance Level | $9.66 | N/A |
| Average True Range (ATR) | 0.18 | 10.58 |
| MACD | -0.01 | 2.68 |
| Stochastic Oscillator | 30.08 | 69.85 |
Price Performance
Historical ComparisonAbout SUZ Suzano S.A.
Suzano SA produces and sells pulp and a variety of paper products. The company organizes itself into two segments based on product type: Pulp and Paper. The Pulp segment generates the majority of revenue. The firm's product portfolio includes printing and writing paper, paperboard, diapers, and sanitary napkins. The company owns forest land and plants in Brazil, where it harvests timber and turns the timber into pulp and paper in its plants.
About AXSM Axsome Therapeutics Inc.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.